First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

This study is testing a new experimental drug called STX-478 to see how well it works and if it is safe for treating advanced solid tumors. The goal is to see if this medicine can stop or slow down cancer cell growth in patients whose tumors have a specific genetic change called a PI3Kα mutation.

This trial is for adults (18+) with advanced solid tumors that have a specific PI3Kα mutation. Participants must be generally healthy enough to carry out daily activities and have tumor tissue available for genetic testing.

You will go through a 28-day screening process to see if you are a good match for the trial. Depending on the study group, you will receive either the new drug alone or in combination with other established hormone or cancer therapies.

This study is currently recruiting volunteers at multiple locations in California and Colorado. You should speak with your doctor to see if one of these centers is a convenient option for you.